Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOSCA-5 study of MZ-004 in chronic total coronary occlusion
2014-004649-28Phase 2Active
- Sponsor
- Matrizyme Pharma
- Start
- May 2015
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of collagenase clostridium histolyticum in Chronic coronary occlusion (CTO) and coronary arteriosclerosis (4 arms), sponsored by Matrizyme Pharma. Primary endpoints: Anterograde PCI success rate and Safety and tolerability. Started May 2015; status: active.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Chronic coronary occlusion (CTO)coronary arteriosclerosis
Beyond the preview
Go deeper on 2014-004649-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004649-28.